News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vaxart, Inc.’s Groundbreaking Tablet Influenza Vaccine Generates Protective Antibody Levels in Humans


6/19/2013 9:47:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than injection, today announced positive safety and immunogenicity data from phase I clinical studies with its oral H1N1 seasonal influenza vaccine candidate. Consequently, the company has initiated a dose-ranging study with its oral H1N1 influenza vaccine. Vaxart is also accelerating development of its oral vaccines for H3N2 influenza and two influenza B-strains, the remaining components of the standard quadrivalent seasonal influenza vaccine.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES